More recently, in 2022, Sun et al. found a de novo SMARCC2 variant in TOF patients, suggesting there may be a link between CHD and deleterious SMARCC2 variants (Sun et al., 2022). This evidence concerns the gene SMARCC2 and coronary artery disorder.